What IsoAid does

IsoAid, LLC is a privately held U.S. medical device manufacturer founded in 2000 and headquartered in Port Richey, Florida (organized under Tennessee law). The company specializes in brachytherapy products for the treatment of localized cancers, with core offerings spanning radioactive seed manufacturing (Advantage I-125 and Advantage Pd-103), proprietary delivery accessories (Secure Strand textured strand, Advantage Seed Magazines with Dose Deflecting Collars), and the FDA-cleared IsoSphere bioabsorbable intracavity device for breast cancer. Its products serve healthcare providers performing prostate, ocular (eye plaque), and breast cancer brachytherapy procedures, and are listed in the joint AAPM/RPC registry and integrated into all major treatment planning software.

The company monetizes through direct hardware sales of seeds and accessories at quote-based, custom-prescribed-activity pricing, supplemented by service revenue from in-house loading, sterilization, and ADCL-calibrated assay. Its go-to-market combines enterprise field sales through territory managers with a minimum of 15 years of brachytherapy experience, a 24/7 customer service operation, an online client portal, and presence at three major oncology conferences (ASBrS, ABS, ASTRO). Two exclusive partnerships anchor the service layer: Dr. Melvin Astrahan / Eye Physics for ocular treatment planning and proprietary plaque technology, and Michael Sitter / Professional Dosimetry Services for prostate treatment planning.

IsoAid operates under ISO 13485 and MDSAP quality certifications with multi-jurisdiction regulatory clearances and IFU documentation in 15+ languages, supporting both U.S. and international sales. The company has no disclosed parent, no known institutional funding, and no publicly reported revenue or headcount, suggesting a founder- or management-owned specialty medical device business focused on niche oncology workflow integration rather than venture-scale growth.

Name

IsoAid

Legal name

IsoAid, LLC

Website

https://isoaid.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Radiation Therapy Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

akta.pro secondary industries

Radiation Processing & Sterilization Services (Medical device sterilization, food irradiation, materials modification) (EUAKAIAG), Sealed Source Manufacturing, Encapsulation & Recycling/Take-Back (Source lifecycle management) (EUAKAIAI)

Keywords

• Brachytherapy seeds
• Radioactive seed implants
• Medical device manufacturing
• Cancer treatment devices
• Prostate brachytherapy

Headquarters

HQ city

Port Richey

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Medical Device Product Sales: Manufacturing and marketing of brachytherapy products including seeds (Advantage I-125 and Pd-103), eye plaques, secure strands, seed magazines, and related accessories. Products sold at prescribed activity levels with in-house loading, sterilization, and assay services.
2. Service Revenue: Full in-house loading, sterilization and assay services for prostate and eye plaque brachytherapy. Treatment planning services through exclusive partnerships. Order fulfillment with ADCL independent assay on all loaded plaques.
3. International Sales: FDA-cleared products sold for diagnostic purposes in the U.S. and internationally, with IFU sheets available in multiple languages including Spanish, Dutch, French, German, Italian, and others.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

IsoAid manufactures and supplies brachytherapy radioactive seeds and associated delivery systems used in the treatment of localized cancers, including prostate, ocular, and breast cancer. Its product line includes I-125 and Pd-103 seeds, stranded seed products (Secure Strand), pre-loaded seed magazines, eye plaque applicator kits, and radioactive seed localization (RSL) needles. The company sells these Class III medical devices to healthcare providers, radiation oncologists, and treatment centers.

Product overview

IsoAid is a premier medical device company manufacturing and marketing full-service Brachytherapy products for treatment of localized cancers. The core product portfolio consists of Advantage I-125 and Advantage Pd-103 radioactive seeds used for prostate, ocular, and breast cancer brachytherapy. Supporting products include Secure Strand (a textured strand exclusive to IsoAid with superior seed retention), Advantage Seed Magazines (shielded cartridges with Dose Deflecting Collars for Mick applicators), Advantage Eye Plaque Applicator Kits, and IsoSphere (a new FDA-cleared bioabsorbable brachytherapy device for breast cancer). The company also provides Radioactive Seed Localization (RSL) needles for diagnostic tumor localization. All products are manufactured under ISO 13485 and MDSAP certifications with in-house loading, sterilization, and assay services.

Differentiator

Problem solved

Functional benefit

Brands

• Advantage: Product line including Advantage I-125 seeds (up to 12 mCi), Advantage Pd-103 seeds (up to 5 mCi), Advantage-Load, Advantage Secure Strand, and Advantage Seed Magazines.
• IsoSphere
• Secure Strand
• COMS Plaques

Products and services

• Advantage I-125 Seed Iodine-125 (I-125) radioactive brachytherapy seed used by radiation oncologists and urologists for permanent interstitial implantation in low-dose-rate (LDR) brachytherapy treatment of localized prostate cancer and other malignancies.
• Advantage Pd-103 Seed
• Secure Strand
• Advantage Seed Magazines
• IsoSphere
• Radioactive Seed Localization (RSL) Needles
• Advantage Eye Plaque Applicator Kit
• Advantage-Load Custom Loaded Seeds

Quantifiable outcome

• 78% more resistant to movement than standard strands
• +2 more outcomes

Segments4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Dr. Melvin Astrahan, PhD / Eye Physics, LLCcoreStrategic or Co-development PartnerExclusive partnership providing access to COMS plaques and over 50 models of Eye Physics collimated plaques, along with proprietary Plaque Simulator advanced 3D planning software. Planning services also provided by Eye Physics for eye plaque brachytherapy treatments.
• Michael Sitter, RT(T) / Professional Dosimetry ServicescoreStrategic or Co-development PartnerExclusive partnership for Prostate Brachytherapy treatment planning services through Michael Sitter at Professional Dosimetry Services (PDS Seattle). Services include feedback from industry experts for treatment planning.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• IsoRay Medical: IsoRay is a direct competitor manufacturing brachytherapy seeds, particularly known for Cesium-131 isotopes used in prostate, brain, and other cancer treatments. They compete head-to-head with IsoAid's I-125 and Pd-103 products in the same clinical indications and hospital customer base.
• Theragenics (now part of BrachySciences/GT Medical Technologies): Theragenics is a direct competitor manufacturing Pd-103 and I-125 brachytherapy seeds (TheraSeed and TheraStrand) and has historically been one of the largest players in the prostate brachytherapy seed market alongside IsoAid. They also sell to healthcare providers with similar treatment planning and loading services.
• Eckert & Ziegler (BEBIG division): Eckert & Ziegler's BEBIG division manufactures I-125, Pd-103, and other brachytherapy seeds (e.g., IsoSeed, Intersource) used in prostate, eye plaque, and other cancer treatments. They are one of the largest global brachytherapy product manufacturers, directly competing with IsoAid's product portfolio.
• Best Medical International: Best Medical International manufactures brachytherapy products including I-125 and Pd-103 seeds, as well as eye plaque applicators and other radiation therapy accessories. They are a direct competitor to IsoAid across multiple product lines, particularly in the seed and applicator categories.

Broad incumbents

• Elekta: Elekta is a global leader in radiation therapy and radiosurgery, offering brachytherapy afterloaders (Flexitron) and treatment planning software used alongside brachytherapy seeds. As a broad incumbent in radiation oncology, Elekta competes with IsoAid by offering the complete ecosystem of hardware, software, and service that hospitals purchase.
• Siemens Healthineers (Varian): Siemens Healthineers (which acquired Varian Medical Systems) is a broad incumbent in radiation oncology, offering linear accelerators, brachytherapy afterloaders, and treatment planning systems. They compete with IsoAid in the broader radiation oncology ecosystem and partner with seed manufacturers.
• Becton Dickinson (BD): BD acquired C.R. Bard, which had a significant brachytherapy product portfolio including I-125 seeds and other oncology products. As a much larger medical device conglomerate, BD represents a broad incumbent competitor with greater R&D and distribution resources.

Emerging players

• iCAD (Xoft): iCAD's Xoft division offers electronic brachytherapy (eBx) systems for breast, skin, and other cancer treatments, providing a radiation-free alternative to radioactive seed brachytherapy. They compete with IsoAid's IsoSphere in the breast IORT market with a different technology approach.
• Sensus Healthcare: Sensus Healthcare provides superficial radiation therapy (SRT) systems primarily for skin cancer and keloid treatment. While not a direct seed competitor, they represent an emerging player in the office-based radiation therapy space, intersecting with some of IsoAid's clinical customer base in radiation oncology.

Others

• Carl Zeiss Meditec: Carl Zeiss Meditec is a medical technology company that provides ophthalmic devices and radiation therapy products, including eye plaque applicators used in ocular cancer treatment. They are a thematically related company in the broader radiation oncology and ocular oncology ecosystem where IsoAid operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IsoAid